Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Net Cash Flow (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Net Cash Flow readings, the most recent being -$122000.0 for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 98.91% to -$122000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$5.6 million, a 73.52% increase, with the full-year FY2025 number at -$16.7 million, down 1958.45% from a year prior.
  • Net Cash Flow hit -$122000.0 in Q1 2026 for Atara Biotherapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $26.6 million in Q4 2022 to a low of -$44.2 million in Q1 2023.
  • Median Net Cash Flow over the past 5 years was -$3.8 million (2024), compared with a mean of -$5.8 million.
  • The widest YoY moves for Net Cash Flow: up 438.95% in 2023, down 890.39% in 2023.
  • Atara Biotherapeutics' Net Cash Flow stood at $26.6 million in 2022, then tumbled by 246.27% to -$38.9 million in 2023, then soared by 45.0% to -$21.4 million in 2024, then skyrocketed by 112.79% to $2.7 million in 2025, then crashed by 104.45% to -$122000.0 in 2026.
  • The last three reported values for Net Cash Flow were -$122000.0 (Q1 2026), $2.7 million (Q4 2025), and -$11.2 million (Q3 2025) per Business Quant data.